Evidence map›Paper›PMID 33679971›Full record

ArticleGastroenterology research and practice2021

The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs.

Hongqiong Yang, Yaojun Zhou, Liangzhi Wang, Tianyi Gu, Mengjia Lv, Jinling Sun, Chao Tu, Junbo He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongqiong YangDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Yaojun ZhouDepartment of Surgical Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.ORCID https://orcid.org/0000-0003-4972-8986
Liangzhi WangDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Tianyi GuDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Mengjia LvDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Jinling SunDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Chao TuDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Junbo HeDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Five electronic databases were searched for eligible records. Outcomes were presented and analyzed according to the objective response rate (ORR), progression-free survival (PFS) rate, and overall survival (OS) rate. Five records involving 2,024 participants were included in the study. The pooled analysis of OS and PFS were longer with ramucirumab (RAM) therapy than without RAM for OS (odds ratio (OR) = 0.90, 95% confidence interval (CI) = 0.82-1.00,

Identifiers

PMID33679971
PMCPMC7925040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.